Eli Lilly: Jurisdictional Issues Raised by Seventh Circuit Threaten Eli Lilly’s Plans to File Retatrutide as a Biologic, Sources Say; Outcome Could Shorten Exclusivity Period and Allow Pharmacies to Compound Knockoff Next-Gen Weight Loss Drug

Eli Lilly (LLY) is battling with the Food and Drug Administration in court over the status of its next-generation GLP-1 weight-loss drug, retatrutide

Published on Oct 01, 2026

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2026 The Capitol Forum. All Rights Reserved.